ReviewNano-micro letters2024
Engineered Cancer Nanovaccines: A New Frontier in Cancer Therapy.
Review in Nano-micro letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.Signal transduction and targeted therapy · 2026Review
- Nanotechnology-Based Cancer Vaccines: Translational Barriers and Emerging Strategies.Vaccines · 2026Review
- Nanoparticle Strategies for Bone Metastasis Immunotherapy: Targeting, Immune Reprogramming and Combination Therapy.Pharmaceutics · 2026Review
- Enhanced Spin-Engineering Photothermoelectric-Enzymatic Catalysis System via Lattice Mismatch-Induced Jahn-Teller Distortion for Tumor Therapy.Nano-micro letters · 2026Article
- Neutrophil Extracellular Traps in Cancer Metastasis: From Mechanistic Understanding to Targeted Therapy.Current oncology (Toronto, Ont.) · 2026Review
- Nanovaccines for lung cancer: Platforms, mechanistic insights, and translational challenges.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Article
- Click Chemistry Mediated Immune Synapse Augmentation in Natural Killer Cell-Cancer Membrane Engagement and Facilitated Anticancer Efficacies of Natural Killer Cell Therapy.Biomaterials research · 2026Article
- Engineering Multimodal Nanomaterials for Prostate Cancer Theranostics: Design Principles, Recent Advances, and Translational Challenges.International journal of nanomedicine · 2026Review
- Concerns and challenges in clinics-guided nanovaccines design and applications.Acta pharmaceutica Sinica. B · 2026Review
- Near-Infrared Conjugated Macrocyclic BODIPYs for Photothermal Cancer Therapy.Angewandte Chemie (International ed. in English) · 2025Article
- Tumor Microenvironment-Responsive Nanomedicines for Potentiating Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Progress and challenges of functionalized bacterial encapsulation: A novel biotechnology for next-generation biotherapeutics.Acta pharmaceutica Sinica. B · 2025Review
- Review
- Enhanced Osteogenic Differentiation of hMSCs Using BMP@ZIF-8-Loaded GelMA Nanocomposite Hydrogels with Controlled BMP-2 Release.ACS omega · 2025Article
- Nano-Oncologic Vaccine for Boosting Cancer Immunotherapy: The Horizons in Cancer Treatment.Nanomaterials (Basel, Switzerland) · 2025Review
- Synergistic tumor microenvironment modulation enabled by a nanozyme-boosted biomimetic macrophage-derived nanovesicle for highly efficient antitumor therapy.Theranostics · 2025Article
- Ultrasound spatiotemporally enables prolonged therapeutic mRNA translation in engineered bacteria for enhanced cancer immunotherapy.Theranostics · 2025Article
- Novel strategies for nanovaccine application in breast cancer treatment.Frontiers in pharmacology · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccinations are essential for preventing and treating disease, especially cancer nanovaccines, which have gained considerable interest recently for their strong anti-tumor immune capabilities. Vaccines can prompt the immune system to generate antibodies and activate various immune cells, leading to a response against tumor tissues and reducing the negative effects and recurrence risks of traditional chemotherapy and surgery. To enhance the flexibility and targeting of vaccines, nanovaccines utilize nanotechnology to encapsulate or carry antigens at the nanoscale level, enabling more controlled and precise drug delivery to enhance immune responses. Cancer nanovaccines function by encapsulating tumor-specific antigens or tumor-associated antigens within nanomaterials. The small size of these nanomaterials allows for precise targeting of T cells, dendritic cells, or cancer cells, thereby eliciting a more potent anti-tumor response. In this paper, we focus on the classification of carriers for cancer nanovaccines, the roles of different target cells, and clinically tested cancer nanovaccines, discussing strategies for effectively inducing cytotoxic T lymphocytes responses and optimizing antigen presentation, while also looking ahead to the translational challenges of moving from animal experiments to clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.